AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6692110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 209
Study 6692110 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin + Metronidazole
Number of subjects: 209
Study 31094783 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% intraoperative oxygen
Number of subjects: 4702
Study 31094783 — intervention group
Group type: COMPARATOR
Intervention: 30% intraoperative oxygen
Number of subjects: 4702
Study 29420518 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Number of subjects: 125
Study 29420518 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 450 mg
Number of subjects: 125
Study 29420518 — intervention group
Group type: COMPARATOR
Intervention: Amaranth dragees (Control)
Number of subjects: 125
Study 27137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy
Number of subjects: 120
Study 27137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser and magnetostimulation
Number of subjects: 120
Study 27137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Number of subjects: 120
Study 27137822 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetostimulation
Number of subjects: 120
Study 24481862 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer advisor intervention (nondirective counseling style)
Number of subjects: 102
Study 24481862 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer advisor intervention (specific goal setting)
Number of subjects: 102
Study 24481862 — intervention group
Group type: EXPERIMENTAL
Intervention: Video assessment tool
Number of subjects: 102
Study 24481862 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire-derived measures
Number of subjects: 102
Study 22317944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamins C and E (200 mg and 400 mg respectively)
Number of subjects: 60
Study 22317944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg) and placebo
Number of subjects: 60
Study 22317944 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg) and placebo
Number of subjects: 60
Study 22317944 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 60
Study 20183736 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis/therapeutic suggestion with standard sedation dose of intravenous anesthetic
Number of subjects: 100
Study 20183736 — intervention group
Group type: COMPARATOR
Intervention: Control group (listened to music)
Number of subjects: 100
Study 18568696 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment based on home BP monitoring
Number of subjects: 236
Study 18568696 — intervention group
Group type: COMPARATOR
Intervention: Usual care with office visits
Number of subjects: 236
Study 16423099 — intervention group
Group type: EXPERIMENTAL
Intervention: Curricular intervention (6-week course on communication and clinical reasoning)
Number of subjects: 100
Study 16423099 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 12523216 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics for acute viral gastroenteritis
Number of subjects: 0
Study 12523216 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics for systemic diseases (e.g., atopic dermatitis)
Number of subjects: 0
Study 9892780 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RM-GIC)
Number of subjects: 33
Study 9892780 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 33
Study 8834648 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuEPO (EPO group)
Number of subjects: 20
Study 8834648 — intervention group
Group type: COMPARATOR
Intervention: No treatment (No-EPO group)
Number of subjects: 20
Study 16296713 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 78
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg (single dose)
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol 80 mg (2 weeks administration, twice daily)
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propranolol (0.2 mg/kg)
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous practolol (1 mg/kg)
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atenolol (0.2 mg/kg)
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous SL 75212 (0.15 and 0.6 mg/kg)
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 100 and 500 μg/ml added to whole blood
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine 5 μg/ml added to whole blood
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol at 1000 ng/ml or less
Number of subjects: 0
Study 6111330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol 5 and 500 μg/ml and 5 mg/ml
Number of subjects: 0
Study 30793920 — intervention group
Group type: EXPERIMENTAL
Intervention: ¼ dose reduction fluoroscopy
Number of subjects: 94
Study 28202072 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini implants (MI)
Number of subjects: 46
Study 28202072 — intervention group
Group type: COMPARATOR
Intervention: Conventional implants (CI)
Number of subjects: 46
Study 25823790 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially evaluated cold pressor (stress induction)
Number of subjects: 101
Study 25823790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control procedure)
Number of subjects: 101
Study 25823790 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg spironolactone (MR availability)
Number of subjects: 101
Study 25823790 — intervention group
Group type: COMPARATOR
Intervention: Placebo (MR blocked)
Number of subjects: 101
Study 23731690 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct application of basic fibroblast growth factor (bFGF)
Number of subjects: 58
Study 23731690 — intervention group
Group type: EXPERIMENTAL
Intervention: Edge approximation alone
Number of subjects: 58
Study 23731690 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 58
Study 21247457 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype in Bai Ku Yao
Number of subjects: 1323
Study 21247457 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype in Han
Number of subjects: 1323
Study 21247457 — intervention group
Group type: COMPARATOR
Intervention: Genotypes in Bai Ku Yao and Han
Number of subjects: 1323
Study 21247457 — intervention group
Group type: COMPARATOR
Intervention: Multivariate linear regression analysis
Number of subjects: 1323
Study 21247457 — intervention group
Group type: COMPARATOR
Intervention: Serum lipid parameters
Number of subjects: 1323
Study 19577021 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (sustained released formulation) administered orally at a daily dose of 16 mg using a periodic dosage regimen (3 wks on, 1 wk off)
Number of subjects: 112
Study 19577021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 17038059 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B CrossAction Power (CAPB) with three different modes of brushing
Number of subjects: 30
Study 17038059 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush Butler GUM 311 (CTB)
Number of subjects: 30
Study 14642054 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 320
Study 14642054 — intervention group
Group type: COMPARATOR
Intervention: Medication treatment alone
Number of subjects: 320
Study 10986526 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive educational nursing intervention
Number of subjects: 179
Study 10986526 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 179
Study 9308061 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion anaesthesia
Number of subjects: 30
Study 9308061 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone induction and isoflurane maintenance
Number of subjects: 30
Study 8418875 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cleft patients treated with presurgical orthopedics
Number of subjects: 103
Study 8418875 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral cleft patients not treated with presurgical orthopedics
Number of subjects: 103
Study 8418875 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cleft patients
Number of subjects: 103
Study 8418875 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleft patients (both unilateral and bilateral)
Number of subjects: 103
Study 8418875 — intervention group
Group type: COMPARATOR
Intervention: Noncleft subjects
Number of subjects: 103
Study 3549794 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid pH 0.6 for 3 min
Number of subjects: 12
Study 3549794 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control)
Number of subjects: 12
Study 30261959 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 10732
Study 30261959 — intervention group
Group type: COMPARATOR
Intervention: High thrombus burden
Number of subjects: 10732
Study 28138830 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression group
Number of subjects: 0
Study 28138830 — intervention group
Group type: COMPARATOR
Intervention: Simple guilty group
Number of subjects: 0
Study 28138830 — intervention group
Group type: EXPERIMENTAL
Intervention: Brainwave-based CIT
Number of subjects: 0
Study 28138830 — intervention group
Group type: EXPERIMENTAL
Intervention: aIAT
Number of subjects: 0
Study 24331637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 99
Study 24331637 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 99
Study 23318497 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with Acipimox (Aci) administration
Number of subjects: 18
Study 23318497 — intervention group
Group type: COMPARATOR
Intervention: Exercise without Acipimox (placebo)
Number of subjects: 18
Study 23318497 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (Aci) administration post-exercise
Number of subjects: 18
Study 20692745 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation approach
Number of subjects: 61
Study 20692745 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation approach
Number of subjects: 61
Study 20692745 — intervention group
Group type: COMPARATOR
Intervention: Both patient groups
Number of subjects: 61
Study 18259012 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine transporter inhibition with 8 mg reboxetine
Number of subjects: 16
Study 18259012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17020983 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel alone (175 mg/m(2)/i.v.)
Number of subjects: 27
Study 17020983 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 days followed by paclitaxel
Number of subjects: 27
Study 15284389 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (S) - 26.6 +/- 4.5 g protein, 44.4 +/- 7.5 mg isoflavones/d
Number of subjects: 40
Study 15284389 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy + probiotics (S+P) - 10(9) colony-forming units Lactobacillus acidophilus DDS+1 and Bifidobacterium longum, 15-30 mg fructooligosaccharide/d
Number of subjects: 40
Study 15284389 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk protein (M) - 26.6 +/- 4.5 g protein/d
Number of subjects: 40
Study 15284389 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk + probiotics (M+P)
Number of subjects: 40
Study 15284389 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - Women without a history of breast cancer
Number of subjects: 40
Study 11500187 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate plus folic acid, vitamin B6 and B12
Number of subjects: 0
Study 11500187 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate plus placebo
Number of subjects: 0
Study 10197170 — intervention group
Group type: EXPERIMENTAL
Intervention: Synovial fluid markers (aggrecan fragments, matrix metalloproteinases-1 and -3, tissue inhibitor of metalloproteinases-1)
Number of subjects: 52
Study 10197170 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum markers (keratan sulfate)
Number of subjects: 52
Study 10197170 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine markers (type I collagen N-telopeptide cross-links)
Number of subjects: 52
Study 10197170 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint fluid aggrecan fragment concentrations
Number of subjects: 52
Study 10197170 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix metalloproteinase-3 concentrations
Number of subjects: 52
Study 8119015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary instrumentation
Number of subjects: 26
Study 8119015 — intervention group
Group type: COMPARATOR
Intervention: Extramedullary instrumentation
Number of subjects: 26
Study 3277506 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (2 g in 60 mL nightly retention enema for 8 weeks)
Number of subjects: 25
Study 3277506 — intervention group
Group type: COMPARATOR
Intervention: Placebo (60 mL nightly retention enema for 8 weeks)
Number of subjects: 25
Study 29091515 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-related goals related to recreation and leisure
Number of subjects: 0
Study 29091515 — intervention group
Group type: EXPERIMENTAL
Intervention: Function-related goals related to walking
Number of subjects: 0
Study 29091515 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance-related goals
Number of subjects: 0
Study 28817199 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological products for the treatment of rheumatoid arthritis
Number of subjects: 0
Study 28817199 — intervention group
Group type: COMPARATOR
Intervention: Placebo/methotrexate control
Number of subjects: 0
Study 26225130 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB supplementation (3×1 gHMB·day(‐1))
Number of subjects: 16
Study 26225130 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration (PLA)
Number of subjects: 16
Study 24188672 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (M-FP)
Number of subjects: 31
Study 24188672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21344046 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of CBT for insomnia and imagery rehearsal therapy
Number of subjects: 22
Study 21344046 — intervention group
Group type: COMPARATOR
Intervention: Usual care comparison group
Number of subjects: 22
Study 18445705 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 200 mg twice daily
Number of subjects: 41
Study 18445705 — intervention group
Group type: EXPERIMENTAL
Intervention: etravirine 400 mg once daily
Number of subjects: 41
Study 18445705 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin 400 mg once daily (positive control)
Number of subjects: 41
Study 18445705 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 41
Study 16480472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal fentanyl (20 microg) added to hyperbaric bupivacaine (2.0 ml of 0.5%)
Number of subjects: 40
Study 16480472 — intervention group
Group type: COMPARATOR
Intervention: Hyperbaric bupivacaine (2.0 ml of 0.5%) with saline (0.4 ml)
Number of subjects: 40
Study 14603404 — intervention group
Group type: EXPERIMENTAL
Intervention: Live presentation mode (n=11)
Number of subjects: 125
Study 14603404 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-group 2-hour virtual (n=8)
Number of subjects: 125
Study 14603404 — intervention group
Group type: COMPARATOR
Intervention: Large-group 2-hour virtual (n=69)
Number of subjects: 125
Study 14603404 — intervention group
Group type: COMPARATOR
Intervention: Large-group virtual in four half-hour sessions across 4 days (n=37)
Number of subjects: 125
Study 11272605 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 40
Study 11272605 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9093498 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving therapy from a trained community nurse
Number of subjects: 70
Study 9093498 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual from general practitioner
Number of subjects: 70
Study 8458463 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day protocol (Tripteriline 0.1, administered daily for 7 days starting on cycle day 2)
Number of subjects: 182
Study 8458463 — intervention group
Group type: COMPARATOR
Intervention: Long protocol (Tripteriline 3.75 mg, administered on cycle day 2)
Number of subjects: 182
Study 8458463 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day protocol
Number of subjects: 182
Study 8458463 — intervention group
Group type: COMPARATOR
Intervention: Long protocol
Number of subjects: 182
Study 2427857 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (0.07 and 0.14 mg/kg)
Number of subjects: 18
Study 2427857 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (0.07 mg/kg)
Number of subjects: 18
Study 28616720 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic radiotherapy of the tumor bed (SRT-TB)
Number of subjects: 59
Study 28616720 — intervention group
Group type: COMPARATOR
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 59
Study 27502721 — intervention group
Group type: EXPERIMENTAL
Intervention: Full (unadjusted) dose of chemotherapy
Number of subjects: 555
Study 27502721 — intervention group
Group type: COMPARATOR
Intervention: Adjusted BSA chemotherapy
Number of subjects: 555
Study 27502721 — intervention group
Group type: COMPARATOR
Intervention: Non-obese patients
Number of subjects: 555
Study 27502721 — intervention group
Group type: COMPARATOR
Intervention: Obese patients receiving full-dose chemotherapy
Number of subjects: 555
Study 27502721 — intervention group
Group type: COMPARATOR
Intervention: Obese patients receiving adjusted BSA chemotherapy
Number of subjects: 555
Study 24060107 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS alone
Number of subjects: 120
Study 24060107 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS combined with sertraline
Number of subjects: 120
Study 24060107 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 120
Study 22052870 — intervention group
Group type: EXPERIMENTAL
Intervention: External lateral stabilization (LS)
Number of subjects: 0
Study 22052870 — intervention group
Group type: EXPERIMENTAL
Intervention: Running without arm swing
Number of subjects: 0
Study 19747986 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with PEG interferon alfa-2b 3.0 mcg/kg/wk for 12 weeks followed by PEG interferon alfa-2b 1.5 mcg/kg/wk for 36 weeks and ribavirin 13 +/- 2 mg/kg daily for 48 weeks
Number of subjects: 610
Study 19747986 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) with PEG interferon alfa-2b 1.5 mcg/kg weekly for 48 weeks and ribavirin 13 +/- 2 mg/kg daily for 48 weeks
Number of subjects: 610
Study 19747986 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy
Number of subjects: 610
Study 19747986 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 610
Study 19747986 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy in patients weighing more than 85 kg
Number of subjects: 610
Study 19747986 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) in patients weighing more than 85 kg
Number of subjects: 610
Study 18477077 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided lateral sagittal infraclavicular block
Number of subjects: 80
Study 18477077 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation-guided lateral sagittal infraclavicular block
Number of subjects: 80
Study 15950851 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (50 mug) with morphine (1 mg) via PCA
Number of subjects: 179
Study 15950851 — intervention group
Group type: COMPARATOR
Intervention: Control (1 mg morphine via PCA)
Number of subjects: 179
Study 12730085 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17beta‐estradiol (E2) 50 microg (tE2 group, n=33)
Number of subjects: 152
Study 12730085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2 1 mg (oE2 group, n=37)
Number of subjects: 152
Study 12730085 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral E2 1 mg combined with gestodene 25 microg (oE2+G group, n=33)
Number of subjects: 152
Study 12730085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=49)
Number of subjects: 152
Study 10493334 — intervention group
Group type: EXPERIMENTAL
Intervention: PNCRM7 vaccine
Number of subjects: 302
Study 10493334 — intervention group
Group type: COMPARATOR
Intervention: PNCRM7 vaccine with hepatitis B vaccine
Number of subjects: 302
Study 10493334 — intervention group
Group type: COMPARATOR
Intervention: PNCRM7 vaccine with DTaP and HbOC
Number of subjects: 302
Study 9020807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotically presented 100/s click trains amplitude modulated with random sequences of 50 or 100 ms square wave-intervals, alternating sound intensities at 60 dB and 80 dB levels with an IID of 20 dB every 2 s.
Number of subjects: 0
Study 9020807 — intervention group
Group type: COMPARATOR
Intervention: Monotically or diotically presented stimuli (not specified in detail).
Number of subjects: 0
Study 1815968 — intervention group
Group type: EXPERIMENTAL
Intervention: Food
Number of subjects: 21
Study 1815968 — intervention group
Group type: COMPARATOR
Intervention: Milk
Number of subjects: 21
Study 1815968 — intervention group
Group type: COMPARATOR
Intervention: Fasting conditions
Number of subjects: 21
Study 6125156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.5 mg
Number of subjects: 0
Study 6125156 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2.0 mg
Number of subjects: 0
Study 6125156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 1.0 mg
Number of subjects: 0
Study 31270136 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation method for total kidney volume (TKV) measurement
Number of subjects: 100
Study 31270136 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated segmentation method for total liver volume (TLV) measurement
Number of subjects: 100